RBC Capital Remains Bullish on Viridian Therapeutics (VRDN) Following Q3 2025 Results

With significant upside potential, Viridian Therapeutics, Inc. (NASDAQ:VRDN) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts. RBC Capital Remains Bullish on Viridian Therapeutics (VRDN) Following Q3 2025 Results On November 6, 2025, RBC Capital raised its price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) from $41 to $45, while maintaining an “Outperform” rating. The investment firm’s bullish stance stemmed from clear visibility toward profitability, se ...